Researchers at Filana Therapeutics have announced progress in developing a new treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy, a condition that affects around 45,000 people in the U.S. This rare genetic disorder often leads to seizures, with 80% to 90% of those with TSC experiencing epilepsy. The company presented their findings at an international conference, highlighting the potential of their drug, simufilam, to address this challenging health issue.

For individuals affected by TSC-related epilepsy, this could mean a new avenue for relief. Current treatments are often ineffective, with more than 60% of patients not responding to available medications. If simufilam proves effective, it could significantly improve seizure control and overall quality of life for those struggling with this condition. The urgency for new treatment options is clear, given the early onset of seizures in many patients, often within their first year of life.

Currently, the research is in an early stage. Filana Therapeutics is working to resolve a clinical hold from the FDA before they can proceed with further trials. This means that while the findings are promising, they have not yet been thoroughly tested in larger human trials. The company is focused on providing additional data to the FDA to move forward with their clinical program.

If you or someone you know is affected by TSC-related epilepsy, staying informed about new treatment developments like simufilam could be beneficial. It’s essential to consult healthcare providers about any new therapies and to keep an eye on updates from Filana Therapeutics as they work through the regulatory process.

Source: globenewswire.com